The OpenAlex profile (ORCID 0000-0002-0928-4754) lists 7 works, 71 total citations, h-index 3, with citations concentrated in 2022β2023 (25 and 35 respectively) and zero recorded for 2024β2026 outputs, which is expected lag for recent publications. A Semantic Scholar record with the same 7 papers shows only 3 total citations and h-index 1, illustrating cross-database indexing discrepancies that complicate precise metric attribution.
The work is methodologically diverse but thematically anchored in cardiac surgery/anesthesia: four RCT meta-analyses (atenolol, propafenone, amiodarone for postoperative atrial fibrillation; TAVI anesthesia modality), a bibliometric analysis of intra-aortic balloon pump use, an in-vitro clotting-time study, and a single-center retrospective heparin sensitivity index study. Deng also appears as a middle author on a music-therapy meta-analysis (34 citations, the most-cited work), a deep-learning radiomics appendicitis model (25 citations), and an HIV/AIDS survival nomogram (11 citations), indicating productive collaboration with Guangzhou/Guangdong clinical groups.
Strengths: PRISMA-compliant meta-analysis methodology, consistency with an established cardiovascular-anesthesia evidence-synthesis group, and one first-author radiology case report in a top journal (Radiology, 2023). Weaknesses/blindspots: portfolio is dominated by secondary research (meta-analyses, bibliometrics) with limited primary data generation; the retrospective heparin study is single-center with unreported sample size in available abstracts; meta-analyses of small RCTs (atenolol, propafenone) inherit underlying small-study bias; no institutional affiliation is confirmed in OpenAlex, and identity fragmentation (three OpenAlex profiles) prevents confident metric attribution. Verdict (BGPT inference): a legitimate, methodologically trained early-career contributor to perioperative evidence synthesis whose independent scientific impact is not yet established; the trajectory is positive but unproven. What would change this conclusion: first-author primary research in high-impact journals, independent grant funding, and sustained citation accrual on 2024β2026 outputs.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.